318 related articles for article (PubMed ID: 28388533)
1. BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.
Cuyàs E; Corominas-Faja B; Martín MM; Martin-Castillo B; Lupu R; Brunet J; Bosch-Barrera J; Menendez JA
Oncotarget; 2017 May; 8(21):35019-35032. PubMed ID: 28388533
[TBL] [Abstract][Full Text] [Related]
2. Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab.
Cuyàs E; Martin-Castillo B; Bosch-Barrera J; Menendez JA
Cell Cycle; 2017 Jun; 16(11):1022-1028. PubMed ID: 28387573
[TBL] [Abstract][Full Text] [Related]
3. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.
Nolan E; Vaillant F; Branstetter D; Pal B; Giner G; Whitehead L; Lok SW; Mann GB; ; Rohrbach K; Huang LY; Soriano R; Smyth GK; Dougall WC; Visvader JE; Lindeman GJ
Nat Med; 2016 Aug; 22(8):933-9. PubMed ID: 27322743
[TBL] [Abstract][Full Text] [Related]
4. RANKL/RANK: from bone loss to the prevention of breast cancer.
Sigl V; Jones LP; Penninger JM
Open Biol; 2016 Nov; 6(11):. PubMed ID: 27881737
[TBL] [Abstract][Full Text] [Related]
5. Can we prevent BRCA1-associated breast cancer by RANKL inhibition?
Kotsopoulos J; Singer C; Narod SA
Breast Cancer Res Treat; 2017 Jan; 161(1):11-16. PubMed ID: 27783278
[TBL] [Abstract][Full Text] [Related]
6. RANKL and RANK: From Mammalian Physiology to Cancer Treatment.
Rao S; Cronin SJF; Sigl V; Penninger JM
Trends Cell Biol; 2018 Mar; 28(3):213-223. PubMed ID: 29241686
[TBL] [Abstract][Full Text] [Related]
7. RANKL/RANK control Brca1 mutation- .
Sigl V; Owusu-Boaitey K; Joshi PA; Kavirayani A; Wirnsberger G; Novatchkova M; Kozieradzki I; Schramek D; Edokobi N; Hersl J; Sampson A; Odai-Afotey A; Lazaro C; Gonzalez-Suarez E; Pujana MA; Cimba F; Heyn H; Vidal E; Cruickshank J; Berman H; Sarao R; Ticevic M; Uribesalgo I; Tortola L; Rao S; Tan Y; Pfeiler G; Lee EY; Bago-Horvath Z; Kenner L; Popper H; Singer C; Khokha R; Jones LP; Penninger JM
Cell Res; 2016 Jul; 26(7):761-74. PubMed ID: 27241552
[TBL] [Abstract][Full Text] [Related]
8. Role of the RANK/RANKL pathway in breast cancer.
Kiesel L; Kohl A
Maturitas; 2016 Apr; 86():10-6. PubMed ID: 26921922
[TBL] [Abstract][Full Text] [Related]
9. Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.
Bayer CM; Beckmann MW; Fasching PA
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):4-11. PubMed ID: 28002265
[TBL] [Abstract][Full Text] [Related]
10. Osteoprotegerin (OPG) mediates the anti-carcinogenic effects of normal breast fibroblasts and targets cancer stem cells through inhibition of the β-catenin pathway.
Alraouji NN; Hendrayani SF; Ghebeh H; Al-Mohanna FH; Aboussekhra A
Cancer Lett; 2021 Nov; 520():374-384. PubMed ID: 34416336
[TBL] [Abstract][Full Text] [Related]
11. The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review.
de Groot AF; Appelman-Dijkstra NM; van der Burg SH; Kroep JR
Cancer Treat Rev; 2018 Jan; 62():18-28. PubMed ID: 29154022
[TBL] [Abstract][Full Text] [Related]
12. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
13. Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
Somasundaram V; Hemalatha SK; Pal K; Sinha S; Nair AS; Mukhopadhyay D; Srinivas P
BMC Cancer; 2016 May; 16():336. PubMed ID: 27229859
[TBL] [Abstract][Full Text] [Related]
14. The Roadmap of RANKL/RANK Pathway in Cancer.
Casimiro S; Vilhais G; Gomes I; Costa L
Cells; 2021 Aug; 10(8):. PubMed ID: 34440747
[TBL] [Abstract][Full Text] [Related]
15. Repurposing denosumab in breast cancer beyond prevention of skeletal related events: Could nonclinical data be translated into clinical practice?
Deligiorgi MV; Panayiotidis MI; Trafalis DT
Expert Rev Clin Pharmacol; 2020 Nov; 13(11):1235-1252. PubMed ID: 33070648
[TBL] [Abstract][Full Text] [Related]
16. Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas.
Zoi I; Karamouzis MV; Xingi E; Sarantis P; Thomaidou D; Lembessis P; Theocharis S; Papavassiliou AG
Breast Cancer Res; 2019 Dec; 21(1):132. PubMed ID: 31796128
[TBL] [Abstract][Full Text] [Related]
17. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
Martin-Castillo B; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Moreno JM; Corominas-Faja B; Urruticoechea A; Martín ÁG; López-Bonet E; Menendez JA
Cell Cycle; 2013 Jan; 12(2):225-45. PubMed ID: 23255137
[TBL] [Abstract][Full Text] [Related]
18. Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers.
Widschwendter M; Burnell M; Fraser L; Rosenthal AN; Philpott S; Reisel D; Dubeau L; Cline M; Pan Y; Yi PC; Gareth Evans D; Jacobs IJ; Menon U; Wood CE; Dougall WC
EBioMedicine; 2015 Oct; 2(10):1331-9. PubMed ID: 26629528
[TBL] [Abstract][Full Text] [Related]
19. Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer.
Kiechl S; Schramek D; Widschwendter M; Fourkala EO; Zaikin A; Jones A; Jaeger B; Rack B; Janni W; Scholz C; Willeit J; Weger S; Mayr A; Teschendorff A; Rosenthal A; Fraser L; Philpott S; Dubeau L; Keshtgar M; Roylance R; Jacobs IJ; Menon U; Schett G; Penninger JM
Oncotarget; 2017 Jan; 8(3):3811-3825. PubMed ID: 28002811
[TBL] [Abstract][Full Text] [Related]
20. The Role of the RANKL/RANK Axis in the Prevention and Treatment of Breast Cancer with Immune Checkpoint Inhibitors and Anti-RANKL.
Simatou A; Sarantis P; Koustas E; Papavassiliou AG; Karamouzis MV
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
